adMare’s Innovation Centre hosts strategic companies playing a key role in the life sciences and health technologies value chain in Montreal and Quebec. Our resident companies are developing a wide range of new innovative healthcare products, and also offer services in medicinal chemistry, assay development, DMPK, intellectual property, and strategic recruitment consulting. We are continuously evolving, so check back regularly to see who’s joined our dynamic ecosystem.
Click on the logo to find more information on our resident companies.
AptoChem specializes in the custom synthesis of stable labeled (D, 13C,15N) and radiolabeled (14C) reference standards, test articles, pharmaceuticals and their metabolites. AptoChem can synthesize a wide variety of small molecules and fine chemicals in the milligram to gram scale. Our goal is to provide our clients with a specialized custom synthetic chemistry service of the highest quality in the industry at the lowest possible price and in shortest possible turnaround time. For more information visit: www.aptochem.com.
Banook Group is one of the few established international providers capable of supplying cardiac safety, central imaging and endpoint adjudication services to pharmaceutical, medical device and biotech companies, CROs and nonprofit organizations. Its mission is to help its clients invent tomorrow’s healthcare, using qualitative, reliable and innovative solutions in early to late stage clinical trials and ultimately to bring new solutions to the market for the benefit of patients worldwide. Its medical and regulatory expertise, quality-driven approach and team availability make the Banook Group a key player for clinical trial services. For more information visit: www.banookgroup.com.
Assay development is a complex process than can rapidly become a bottleneck in both basic research and drug discovery laboratories. BioAuxilium Research provides customized services in biochemical, cell-based and biomarker assay development across a number of therapeutic areas using various high-throughput technology platforms.
BioAuxilium also offers preclinical sample testing services using no-wash immunoassay technologies. Regardless of the scope of your project, we can design and develop a robust, sensitive and reproducible assay that will meet your requirements and expectations. For more information visit: www.bioauxilium.com.
The CERASP, a centre of excellence in pharmaceutical innovation, has as its mission to develop and support applied research, training and technology transfer related to the discovery, development and evaluation of innovative solutions in the pharmaceutical field, in particular: Biopharmacy, Pharmaceutical technology, Pharmaceutical production and Digital health.
The Centre provides support primarily to small and medium-sized businesses involved in the development and manufacturing of pharmaceuticals, natural health products and cosmetics. Our expertise in the areas of formulation, manufacturing, technology transfer, quality systems, and regulatory affairs. For more information visit: www.cerasp.ca.
Cerebrasol Ltd. specializes in the design and delivery of focused preclinical research packages, using electrophysiological recording techniques for nervous system indications such as pain, neurodegeneration (Alzheimer’s and Parkinson’s disease), psychiatric disorders, movement disorders and obesity. We prepare your compounds for clinical development by providing a flexible, highly skilled service with fast turnaround tailored to our clients’ needs, delivering key proof-of-concept, drug efficacy, mechanism of action data and more. For more information visit: www.cerebrasol.com.
Chorus, an autonomous division of Eli Lilly and Company, is an early phase drug development group that cost-effectively advances candidate molecules from discovery through clinical Proof of Concept (PoC).
The Chorus mission is to deliver definitive, quality PoC data enabling our business partners to efficiently sort a large stream of innovative candidates. The goal of Chorus is to deliver PoC data that permits informed go-no go investment decisions and, in the case of successful assets, drives a large step-up in probability of technical success and value. We do this by combining an integrated, virtual drug development platform with a more efficient drug development paradigm to deliver best-in-industry productivity. Taking the Chorus approach to early stage development, our business partners can markedly reduce the cost of early technical attrition while maintaining a call back option for promising assets. For more information visit: www.choruspharma.com.
Cura Therapeutics is developing innovative immunotherapies to cure cancer and infectious diseases. Their technologies harness cytokines to create multi-functional proteins with potent anti-cancer and antiviral properties. For more information visit: www.curatherapeutics.com.
Cyclenium Pharma is an emerging pharmaceutical research and development company pursuing development of selected product opportunities in areas of unsatisfied medical need, while simultaneously creating a second generation macrocyclic drug discovery technology. We are building value through progression of our internal programs, and establishing collaborations with innovative pharmaceutical and biotechnology companies seeking to drug difficult disease targets. For more information visit: www.cyclenium.com.
Domain Therapeutics NA is the Canadian subsidiary of Domain Therapeutics, a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets.
Domain Therapeutics discovers GPCR drugs by exploiting its innovative and differentiated technologies. The company’s pipeline is composed of new chemical entities, ranging from hits to preclinical candidates for significant CNS and metabolic disorders.
Establishing a presence in Montreal is part of the company’s strategy for bringing to market a new GPCR-specific biosensor technology, BioSens-All(TM), developed at the Institute of Research in Immunology and Cancer (IRIC) of the University of Montreal in the team of Professor Michel Bouvier. BioSens-All(TM) technology enables a deeper understanding of the GPCR signaling pathways that are activated by each candidate molecule and thus predict its pharmacological profile. For more information visit: www.domaintherapeutics.com.
enGene is leader in nucleotide delivery to the intestine. The Company has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. enGene’s platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic delivery of therapeutic proteins from the gut to treat diabetes, anemia, hemophilia and others. The Company is initially applying its technology to localize delivery of immune-modulating proteins to the intestinal mucosa for treating inflammatory bowel disease. For more information visit: www.engeneinc.com.
Inception Sciences Canada is a small molecule drug discovery company. Our focus is creating high-value therapies with transformative potential to address diseases and disorders with significant unmet needs. Through partnerships with academic experts, we are translating biological insights into first-in-class drugs. For more information visit: www.inceptionsciences.com.
A medicinal chemistry-focused R&D organization specializing in identifying novel leads and optimizing them as successful clinical candidates. We have an established track record with clinical candidates in psychosis, depression, Alzheimer’s and pain. We provide full discovery support (computational chemistry, design, synthesis, and DMPK) to our partners in pharma and biotech where innovation and proven delivery-expertise are needed. For more information visit: www.intellisynrd.com.
Jenthera develops novel CRISPR therapeutics using its proprietary precision gene editing platform allowing for the performance of advanced full spectrum gene editing. Unlocking an unprecedented array of possibilities for the tackling of genetic diseases, our technology aims at the development of groundbreaking therapeutics in oncology, cardiovascular indications, cell therapies and for broader polygenic gene editing. For more information visit: www.jenthera.com.
KDM is a contract research organization providing services to the biotech and pharmaceutical industry. We offer services to help clients identify key aspects in PK, PD, and metabolism to move projects forward. These services include analytical and bioanalytical method development/validation, analytical and bioanalytical analysis of samples in various in vitro, preclinical and clinical matrixes, impurity and metabolite structure elucidation, and experimental evaluation of physical chemistry and pharmaceutical properties including drug metabolism, drug-drug interaction, plasma protein binding, solubility, stability, and formulations. For more information visit: www.kdmlabs.com.
Modelis is accelerating drug discovery for rare genetic diseases. For more information visit: www.modelis.ca.
Molecular Forecaster Inc. is a Canadian, Montreal-based scientific software company that distributes the FORECASTER and VIRTUAL CHEMIST computational platforms while offering contract research services. These platforms are used for drug discovery, metabolism prediction, combinatorial chemistry, and catalyst design. We currently service clients in small biotechnology and larger pharmaceutical companies, whereas we provide our software free for academic research. We are a team of specialized scientists with work experience in medicinal, synthetic, and computational chemistry. We leverage our knowledge of chemical principles to investigate and solve chemical and biochemical problems virtually; we develop our own high accuracy programs with unique, customizable features. For more information visit: www.molecularforecaster.com.
Nuchem is a drug discovery and chemical development contract research organization located in the Greater Montreal area in Canada supporting biotech and pharmaceutical companies worldwide. The senior team members have extensive experience in drug discovery project management. This expertise was developed while working in a broad range of therapeutic areas including inflammation, diabetes, bone, obesity, infectious diseases, cancer and pain. Nuchem has established a diverse customer base of biotech, pharma and academic research laboratories within North America providing services such as Synthetic Organic Chemistry, Medicinal Chemistry, Process Chemistry, Cellular Biology, Biochemistry, Pharmacology, Analytical and Bioanalytical Chemistry. For more information visit: www.nuchemsciences.com.
An innovative company with an aim to significantly improve efficiency of drug discovery process from lead identification through lead optimization to development candidates. With an excellent team of highly creative drug discovery scientists trained in world reputed laboratories and deep experience in drug discovery & development from pharmaceutical companies such as Merck, Pfizer, Wyeth, Schering-Plough, AstraZeneca and Boehringer-Ingelheim, we offer collaborative opportunities to provide most efficient solutions. For more information visit: www.parazapharma.com.
Progeneca Biotech provides quality services to small and large biotech companies as well as to the academic sector. Amongst the services we provide are gene cloning, expression, purification of proteins and small molecules, protein modification, protein characterization, in-vitro assays using spectrophotometer, fluorescence, HPLC and chromatography based assays, biomarkers enrichment & proteomics, mass spectrometry analyses, Pre-IND and IND filing and consultancy. We have vast experience in Analytical methods development as required by FDA and its Canadian and European counterparts. Our expertise in protein drug R&D, from cloning to purified protein product, can shorten R&D time and can facilitate faster drug development processes. For more information visit: www.progeneca.com.
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. For more information visit: www.reparerx.com.
Stratuscent Inc. develops CLOUDSENSE, an electronic nose platform. CLOUDSENSE is a ubiquitous chemical sensing platform technology that can quantify and identify chemical footprints that are omnipresent in our environment. The ability to sense chemical fingerprints in a ubiquitous computing environment can provide the context to the decision making process in smart devices. For more information visit: www.stratuscent.com.
Targa Biomedical is a biotechnology company developing pharmacological assets optimizing the manufacturing quality and clinical impact of cell therapy and increasing opportunities for life-saving organ transplantation. For more information visit: www.targabiomedical.com.
Trepso Therapeutics is developing novel therapeutics to reverse the structural deterioration associated with degenerative disc and articular joint diseases, such as osteoarthritis, and to reduce the associated pain and inflammation.
Valence Discovery is an interdisciplinary team of scientists and engineers out of Mila – Quebec AI institute developing new machine learning technologies for molecular design and optimization. For more information visit: www.valencediscovery.com.
Ventus is focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer. Ventus uniquely enabled by its field-leading structural immunology platform, a highly experienced management and drug discovery team that has delivered multiple marketed compounds, and leading academics spanning the fields of structural biology and immunology. Guided by a patient-centric ethos, its aim is to rapidly advance multiple drug candidates. Its emerging pipeline focuses on the inflammasome and nucleic acid sensing pathways. For more information visit: www.ventustx.com.